Key Developments: Bio-Rad Laboratories Inc (BIO)

BIO on New York Consolidated

121.31USD
19 Dec 2014
Price Change (% chg)

$0.53 (+0.44%)
Prev Close
$120.78
Open
$120.76
Day's High
$121.83
Day's Low
$120.36
Volume
142,730
Avg. Vol
104,068
52-wk High
$134.13
52-wk Low
$102.71

Search Stocks

Latest Key Developments (Source: Significant Developments)

Bio-Rad Laboratories receives premarket application approval for Geenius HIV 1/2 supplemental assay
Tuesday, 18 Nov 2014 04:15pm EST 

Bio-Rad Laboratories Inc:Receives Premarket Application approval from the U.S. Food and Drug Administration for Bio-Rad's Geenius HIV 1/2 Supplemental Assay (test).Geenius HIV 1/2 Supplemental Assay is a single-use immunochromatographic assay intended for use as an additional test to confirm the presence of and differentiate antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV-1 and HIV-2).  Full Article

Bio-Rad Laboratories Inc reaffirms FY 2014 revenue guidance-Conference Call
Tuesday, 4 Nov 2014 05:00pm EST 

Bio-Rad Laboratories Inc:Says it continue to anticipate FY 2014 currency neutral sales growth of around 2.5 pct and in line with the guidance set at the beginning of the year.Reported revenue of $2.132 bln in FY 2013.FY 2014 revenue of $2.179 bln - Thomson Reuters I/B/E/S.  Full Article

Bio-Rad Laboratories Inc reaffirms FY 2014 revenue guidance-Conference Call
Tuesday, 5 Aug 2014 05:00pm EDT 

Bio-Rad Laboratories Inc:Says it remains cautiously optimistic of achieving the currency-neutral sales growth guidance of 2.5 pct for FY 2014 that was laid out at the beginning of the year.Reported revenue of $2.13 bln in FY 2013.FY 2014 revenue of $2.19 bln - Thomson Reuters I/B/E/S.  Full Article

Bio-Rad Laboratories Inc acquires GnuBIO and DNA sequencing technology
Thursday, 10 Apr 2014 08:00pm EDT 

Bio-Rad Laboratories Inc:Announced that it has purchased GnuBIO, Inc.Terms of the transaction were not disclosed.  Full Article

Bio-Rad Laboratories Inc lowers FY 2013 revenue guidance - Conference Call
Thursday, 7 Nov 2013 05:00pm EST 

Bio-Rad Laboratories Inc:Says FY 2013 it guided currency-neutral revenue growth to be in the 3% to 3.5% range for the base business, and 3.5% to 4% including Serotec.Says it also told that any further deterioration in Europe, or funding in the academic and government research markets, could make goals difficult to achieve.Says given year-to-date currency-neutral growth of about 2% for the base business, and 3.1% including Serotec, and combined with the continued European challenges and constrained funding environment.Says it now believe FY 2013 currency-neutral sales growth will likely remain in that same 2% to 3% range it has experienced so far this year.Says it reported revenue of $2.069 billion in fiscal 2012.FY 2013 revenue of $2.139 billion - Thomson Reuters I/B/E/S Estimates.  Full Article

Bio-Rad Laboratories Inc Announces Appointment Of Auditor-Form 8-K
Wednesday, 9 Oct 2013 04:42pm EDT 

Bio-Rad Laboratories Inc reported in its Form 8-K that on October 8, 2013, Bio-Rad Laboratories, Inc. (Company) engaged KPMG LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2013 based on the recommendation and authorization of the Audit Committee of its Board of Directors.  Full Article

Bio-Rad Laboratories Inc Reaffirms FY 2013 Revenue Guidance-Conference Call
Tuesday, 6 Aug 2013 05:00pm EDT 

Bio-Rad Laboratories Inc announced that for fiscal 2013, it remain cautiously optimistic of achieving the currency-neutral sales growth guidance of 3% to 3.5% for the base business it provided last February as well as expectation of a 3.5% to 4% topline growth when including the Serotec sales. The Company reported revenue of $2.069 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.149 billion for fiscal 2013.  Full Article

Bio-Rad Laboratories Inc Reaffirms FY 2013 Revenue Guidance-Conference Call
Tuesday, 7 May 2013 05:00pm EDT 

Bio-Rad Laboratories Inc announced that for fiscal 2013, the Company is cautiously optimistic of achieving a currency-neutral sales growth guidance of 3% to 3.5% for the base business that the Company provided in February. The Company reported revenue of $2.069 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.15 billion for fiscal 2013.  Full Article

Bio-Rad Laboratories Inc Issues FY 2013 Revenue Guidance Above Analysts' Estimates-Conference Call
Tuesday, 26 Feb 2013 10:00pm EST 

Bio-Rad Laboratories Inc announced that for fiscal 2013, it expects currency neutral sales growth to be in the 3% to 3.5%. The Company reported revenue of $2.069 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.12 billion for fiscal 2013.  Full Article

Bio-Rad Laboratories Inc Acquires AbD Serotec, Division Of MorphoSys AG
Thursday, 10 Jan 2013 09:05am EST 

Bio-Rad Laboratories Inc announced that it has purchased AbD Serotec, a division of MorphoSys AG, for approximately 53 million euros in cash. AbD Serotec is one of the antibody manufacturers offering over 15,000 antibodies, kits, and accessories. AbD Serotec has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom, as well as other facilities in Germany and the U.S.  Full Article

Search Stocks